A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-25 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
=== Side effects === Side effects of laudanum are generally the same as with morphine, and include euphoria, dysphoria, pruritus, sedation, constipation, reduced tidal volume, respiratory depression, as well as psychological dependence, physical dependence, miosis, and xerostomia. Overdose can result in severe respiratory depression or collapse and death. The ethanol component can also induce adverse effects at higher doses; the side effects are the same as with alcohol. Long-term use of laudanum in nonterminal diseases is discouraged due to the possibility of drug tolerance and addiction. Long-term use can also lead to abnormal liver function tests; specifically, prolonged morphine use can increase ALT and AST blood serum levels.
Biden earned a Juris Doctor from Syracuse University College of Law in 1968. In his first year of law school, he failed a course because he plagiarized a law review article, but the failing grade was later stricken. His grades were relatively poor, and he graduated 76th in a class of 85. He was admitted to the Delaware bar in 1969. Biden clerked at a law firm headed by prominent local Republican William Prickett in 1968 and self-identified as a Republican. He disliked incumbent Democratic Delaware governor Charles L. Terry's conservative racial politics and supported a more liberal Republican, Russell W. Peterson, who defeated Terry in 1968. Local Republicans attempted to recruit Biden, but he registered as an independent because of his distaste for Republican presidential candidate Richard Nixon.
Poor control of T2DM results in high levels of glycated hemoglobin in the red blood cells. The normal reference range is approximately 4.0–5.9%. Though difficult to obtain, values less than 7% are recommended for people with T2DM. Levels greater than 9% are associated with poor control of the glycated hemoglobin, and levels greater than 12% are associated with very poor control. Diabetics who keep their glycated hemoglobin levels close to 7% have a much better chance of avoiding the complications that may accompany diabetes (than those whose levels are 8% or higher). In addition, increased glycated of hemoglobin increases its affinity for oxygen, therefore preventing its release at the tissue and inducing a level of hypoxia in extreme cases. Elevated levels of hemoglobin are associated with increased numbers or sizes of red blood cells, called polycythemia. This elevation may be caused by congenital heart disease, cor pulmonale, pulmonary fibrosis, too much erythropoietin, or polycythemia vera. High hemoglobin levels may also be caused by exposure to high altitudes, smoking, dehydration (artificially by concentrating Hb), advanced lung disease and certain tumors.
On August 29, 1949, the Soviet Union tested its first nuclear weapon at Semipalatinsk in Kazakhstan (see also Soviet atomic bomb project). Scientists in the United States from the Manhattan Project had warned that, in time, the Soviet Union would certainly develop nuclear capabilities of its own. Nevertheless, the effect upon military thinking and planning in the United States was dramatic, primarily because American military strategists had not anticipated the Soviets would "catch up" so soon. However, at this time, they had not discovered that the Soviets had conducted significant nuclear espionage of the project from spies at Los Alamos National Laboratory, the most significant of which was done by the theoretical physicist Klaus Fuchs. The first Soviet bomb was more or less a deliberate copy of the Fat Man plutonium device. In the same year the first US-Soviet nuclear war plan was penned in the US with Operation Dropshot. With the monopoly over nuclear technology broken, worldwide nuclear proliferation accelerated. The United Kingdom tested its first independent atomic bomb in 1952, followed by France developing its first atomic bomb in 1960 and then China developing its first atomic bomb in 1964. While much smaller than the arsenals of the United States and the Soviet Union, Western Europe's nuclear reserves were nevertheless a significant factor in strategic planning during the Cold War.
Sources: en.wikipedia.org
== Stages == adrenarche (approximately ages 6–8) gonadarche (approximately age 10½ in females and age 11½ in males) thelarche (approximately age 10½ in females) pubarche (approximately age 11 in females and age 12 in males) menarche (approximately age 12½ in females) spermarche (approximately age 13 in males)
Southern Rhodesia's fighting contributions in Britain and western Europe were primarily in the air, as part of the much larger Allied forces. Rhodesian pilots and Allied airmen trained in the colony's flying schools participated in the defence of Britain throughout the war, as well as in the strategic bombing of Germany and other operations. Rhodesia provided the only RAF flying ace of the Norwegian Campaign of April–June 1940, Squadron Leader Caesar Hull. Later that year "The Few", the Allied airmen of the Battle of Britain, included three pilots of Southern Rhodesian birth—Hull, Pilot Officer John Chomley and Flight Lieutenant John Holderness—of whom two, Hull and Chomley, lost their lives. Two of the RAF's three Rhodesian squadrons, Nos. 44 and 266, operated from England during the war. No. 266 (Rhodesia) Squadron, a fighter squadron based in Cambridgeshire for most of the duration, was initially only nominally Rhodesian, being manned by a mixture of British and Commonwealth personnel, but it received more airmen from the colony gradually and was virtually all Rhodesian by August 1941. Initially flying Spitfires, it switched to Typhoons in early 1942. It took as its motto the Sindebele word Hlabezulu ("Stabber of Skies") and first went into action over Dunkirk on 2 June 1940, after which it fought in the Battle of Britain. The squadron's duties thereafter included patrolling, protecting convoys, sweeping around northern France and the Belgian and Dutch coasts, and escorting bombing raids over France and the Rhine. No.
That is how this entire mass of suffering originates.The Mahahatthipadopama-sutta (M 28) contains another short explanation of dependent origination:these five grasping aggregates are indeed dependently originated. The desire, adherence, attraction, and attachment for these five grasping aggregates is the origin of suffering. Giving up and getting rid of desire and greed for these five grasping aggregates is the cessation of suffering.
Sources: en.wikipedia.org
Development of self-glowing actinide-doped materials with durable crystalline matrices is a new area of actinide utilization as the addition of alpha-emitting radionuclides to some glasses and crystals may confer luminescence.
== Mechanisms of hepatotoxicity == Since the withdrawal in 2000, mechanisms of troglitazone hepatotoxicity have been extensively studied using a variety of in vivo, in vitro, and computational methods. These studies have suggested that hepatotoxicity of troglitazone results from a combination of metabolic and nonmetabolic factors. The nonmetabolic toxicity is a complex function of drug-protein interactions in the liver and biliary system. Initially, the metabolic toxicity was largely associated with reactive metabolite formation from the thiazolidinedione and chromane rings of troglitazone. Moreover, the formation of quinone and o-quinone methide reactive metabolites were proposed to be formed by metabolic oxidation of the hydroxy group (OH group) of the chromane ring. Detailed quantum chemical analysis of the metabolic pathways for troglitazone has shown that quinone reactive metabolite is generated by oxidation of the OH group, but o-quinone methide reactive metabolite is formed by the oxidation of the methyl groups (CH3 groups) ortho to the OH group of the chromane ring. This understanding has been recently used in the design of novel troglitazone derivatives with antiproliferative activity in breast cancer cell lines.
In October 2008, Pierre-Emmanuel Thomann wrote in Défense nationale et sécurité: "This conflict is, above all, the multipolar world's first war. [...] The conflict between Russia and Georgia is larger than a local territorial affair and will have repercussions on a regional and worldwide scale. [...] Its presence in South Ossetia, close to the territorial heart of Georgia, enables Russia to reach the capital Tbilisi very rapidly, to cut the country's main east-west communications corridor, and to neutralise the Baku-Tbilisi-Ceyhan oil pipeline, which supplies the world markets and passes south of the Georgian capital. [...] Russia's priority to break its encirclement by the Atlantic Alliance has been achieved." On 11 November 2008, Melik Kaylan wrote in Forbes: "There is an additional misconception that [...] the Bush administration encouraged Saakashvili to confront the Russians or at least bolstered his sense of allied support. This is manifestly untrue. Tbilisi insiders told me that Georgia had been asking the Bushies for anti-aircraft missiles for some years.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.